Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
To compare daclatasvir + asunaprevir (DCV + ASV) versus sofosbuvir/ledipasvir (SOF/LDV) for hepatitis C virus genotype 1b in Japanese patients without NS5A polymorphisms at L31 and Y93H. All Phase III trials of SOF/LDV and DCV + ASV conducted in Japan were included. To adjust for cross-trial differences, DCV + ASV patients were weighted to match reported SOF/LDV summary baseline characteristics. After adjustment, the rate of SVR12 (99.3 vs 100%; p = 0.398) and discontinuation due to adverse events (1.3 vs 0.0%; p = 0.327) were similar between patients treated with DCV + ASV (n = 252) and SOF/LDV (n = 171). After adjusting for cross-trial differences in baseline characteristics, DCV + ASV and SOF/LDV were associated with similar efficacy and discontinuation due to adverse events in the treatment of hepatitis C virus genotype 1b in Japanese patients without NS5A polymorphisms.